Standards of Medical Care in Diabetes-2022
American Diabetes Association (ADA)
Atherosclerotic cardiovascular disease (ASCVD)
Chronic kidney disease (CKD)
Glucagon-like peptide 1 receptor agonists (GLP-1RAs)
Sodium–glucose cotransporter 2 inhibitors (SGLT2i)
American Diabetes Association (ADA) presents “the Standards of Medical Care in Diabetes-2022” on Jan 1, 2022. Metformin has been for long years strongly recommended as a first-line agent for type 2 diabetes mellitus (T2DM). In latest edition, metformin becomes not necessarily first-line, for atherosclerotic cardiovascular disease (ASCVD), heart failure or chronic kidney disease (CKD). For initial combination therapy, glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) can be applied. If eGFR is 25 mL/min/1.73m2 < or urinary albumin is 300 mg/gCr <, SGLT2i is required to prevent CKD progression and to suppress cardiovascular risk.
SunText Review of Endocrine Care
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
srec_1_1_106.pdf 345 KB